EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

GM1 Ganglioside as a Disease-Modifying Therapeutic for Parkinson’s Disease: A Multi-Functional Glycosphingolipid That Targets Multiple Parkinson’s Disease-Relevant Pathogenic Mechanisms

Jay S Schneider iD

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms24119183 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Jay S Schneider. Beteiligte Einrichtung: Department of Pathology and Genomic Medicine, Thomas Jefferson University, Philadelphia, PA 19107, USA. Hauptthemen laut MEDLINE: Parkinson Disease. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIEHS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Parkinson’s disease (PD) is a progressive neurodegenerative disorder affecting millions of patients worldwide. Many therapeutics are available for treating PD symptoms but there is no disease-modifying therapeutic that has been unequivocally shown to slow or stop the progression of the disease. There are several factors contributing to the failure of many putative disease-modifying agents in clinical trials and these include the choice of patients and clinical trial designs for disease modification trials. Perhaps more important, however, is the choice of therapeutic, which for the most part, has not taken into account the multiple and complex pathogenic mechanisms and processes involved in PD. This paper discusses some of the factors contributing to the lack of success in PD disease-modification trials, which have mostly investigated therapeutics with a singular mechanism of action directed at one of the many PD pathogenic processes, and suggests that an alternative strategy for success may be to employ multi-functional therapeutics that target multiple PD-relevant pathogenic mechanisms. Evidence is presented that the multi-functional glycosphingolipid GM1 ganglioside may be just such a therapeutic.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Parkinson DiseaseHumansG(M1) GangliosideGlycosphingolipidsGangliosides

Stichwörter der Autor:innen

GM1 gangliosideParkinson’s diseasedisease modification

Substanzen

G(M1) GangliosideGlycosphingolipidsGangliosides

Autor:innen und Institutionen

  • Department of Pathology and Genomic Medicine, Thomas Jefferson University, Philadelphia, PA 19107, USA.

ORCID-Profile: Jay S Schneider

Förderung

  • NIEHS NIH HHS

Zitieren

APA

Schneider, J. S. (2023). GM1 Ganglioside as a Disease-Modifying Therapeutic for Parkinson’s Disease: A Multi-Functional Glycosphingolipid That Targets Multiple Parkinson’s Disease-Relevant Pathogenic Mechanisms. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24119183

Vancouver

Schneider JS. GM1 Ganglioside as a Disease-Modifying Therapeutic for Parkinson’s Disease: A Multi-Functional Glycosphingolipid That Targets Multiple Parkinson’s Disease-Relevant Pathogenic Mechanisms. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24119183

BibTeX
@article{Schneider2023,
  author = {Schneider, Jay S},
  title = {GM1 Ganglioside as a Disease-Modifying Therapeutic for Parkinson’s Disease: A Multi-Functional Glycosphingolipid That Targets Multiple Parkinson’s Disease-Relevant Pathogenic Mechanisms},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms24119183}
}
Kostenlos starten →